Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NovoCure Ltd.
NovoCure Ltd.
Merck Sharp & Dohme LLC
Duke University
Daiichi Sankyo
University of Kentucky
Albert Einstein College of Medicine
Pfizer
Emory University
NeoImmuneTech
Jiangsu HengRui Medicine Co., Ltd.
University of Nebraska
Merck Sharp & Dohme LLC
Medical University of South Carolina
BeOne Medicines
University of Vermont
Merck Sharp & Dohme LLC
Boehringer Ingelheim
Big Ten Cancer Research Consortium
Big Ten Cancer Research Consortium
Genentech, Inc.
Exelixis
Novartis
AstraZeneca
Bristol-Myers Squibb
BeOne Medicines
Bristol-Myers Squibb
Bristol-Myers Squibb
Massachusetts General Hospital
Rutgers, The State University of New Jersey
I-Mab Biopharma US Limited
Hoffmann-La Roche
Fundación GECP
Mayo Clinic
Tesaro, Inc.
Daiichi Sankyo
AstraZeneca
AstraZeneca
Pfizer
University of California, Davis
Boehringer Ingelheim
Stanford University
Pfizer
Bristol-Myers Squibb
Swiss Cancer Institute
University of Southern California
Duke University
NRG Oncology
Addario Lung Cancer Medical Institute
Memorial Sloan Kettering Cancer Center
BerGenBio ASA